Pneumoniaself-testNCT03256604
A Sputum Screening Test to Rule-out Pneumonia at an Early Stage
An observational study of Pneumonia and Community-acquired Pneumonia, run by University Hospital, Linkoeping at 1 site in Sweden.
Trial summary
In patients with clinical symptoms of respiratory infection, rapid identification of cases requiring antibiotic therapy is crucial to avoid development of multiple resistant bacteria. Identification of local acute-phase reactants can help assess the host's response to bacterial infection at the injury site. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Pneumonia, Community-acquired Pneumonia, Exacerbation Copd
- What is being tested?
- left-over sputum
- How many people
- 467 participants
- Where
- 1 siteSweden
- Study dates
- Nov 2015to Apr 2016
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: All cases that searched the open Health care specialist facility at Linkoeping University hospital or were admitted to the ward at different clinics at the University Hospital in Linkoeping between 1st November 2015 to 30th January 2016 due to suspected respiratory infection and sputum samples were collected to be cultured at the Department of Microbiology University Hospital in Linkoeping.
Who may be able to join
- Sputum samples collected for routine diagnostic and reached the laboratory within 12 hours after Collection and considered as representative by microscopy and kept 4-8 C after Culture.
Who cannot join
- Samples not collected as above
Trial locations and contacts
1 site in 1 country.
About this study
In patients with clinical symptoms of respiratory infection, rapid identification of cases requiring antibiotic therapy is crucial to avoid development of multiple resistant bacteria. Identification of local acute-phase reactants can help assess the host's response to bacterial infection at the injury site. Here, the investigators developed an affordable, stable, feasible, and accurate diagnostic tool based on a locally produced protein with specific binding affinity to polysaccharides. The investigators further evaluated the ability of the novel test strip to rule out pneumonia.
Read the detailed description
A lower respiratory tract infection is a serious situation that can abruptly become complicated by sepsis, respiratory failure, lung tissue necrosis, and multiple organ dysfunction. Hence, empiric antibiotic treatment is commonly initiated as soon as infection is suspected and cultures and/or other diagnostic tests are procured, representing a major reason for antibiotic prescription. Widespread antibiotic overuse and misuse have led to the emergence of multiple resistant bacterial strains, posing a major health threat. There exists a critical need for practical solutions to prevent antibiotic overuse, especially in communities where antibiotics are available without prescription.
Pathophysiologic studies show that infection does not result from bacterial or viral overgrowth alone, but rather from the microorganisms' penetration beyond the host immune system. Therefore, infection assessment requires investigation of both microorganism presence and the defense mechanisms activated within the patient's body. Bacteria overgrowth leads to lung tissue inflammation, recruitment of white blood cells to the infected area, and chemokine and cytokine production and release, which can cause the alveoli to become filled with fluid, leading the patient to develop a cough with phlegm or pus, fever, chills, and dyspnea.
Microbiological diagnosis of lower respiratory tract infections requires assessment of the invading microorganism by examination of sputum using microscopy, quantitative culture, and PCR. However, such microbiological investigations have limited value in pneumonia management. Polymicrobial flora make it difficult to interpret cultures from patients with chronic bronchitis. It is also difficult to evaluate cultures from nosocomial pneumonia since the pathogenic bacteria are often identical to those appearing in the throat flora. Immunosuppressed patients frequently produce sputum containing low number of white blood cells. The patient's clinical signs, such as respiratory and circulatory status, are the most reliable markers for determining treatment efficacy.
In practice, most physicians choose to examine additional markers at early stages to closely monitor the effects of therapy, particularly in high-risk patients who have been admitted to intensive care units. Commonly used systemic markers include body temperature, C-reactive protein (CRP), procalcitonin (PCT), and interleukin 6 (IL-6). Hepatocyte growth factor (HGF) concentration reportedly increases during organ damage, such as that caused by infectious diseases. Studies show increased HGF concentrations in serum and exhaled-breath condensate from patients with pneumonia, with HGF presence being significantly correlated with survival. Moreover, HGF levels markedly decrease within 48 hours of initiating appropriate antibiotic therapy. Surface plasmon resonance (SPR) results indicate that HGF produced during acute infection shows high affinity for the extracellular matrix component heparan sulfate proteoglycan (HSPG). These findings suggest that HGF assessment in sputum could be a tool for detecting bacterial infection at the site of injury.
Proteins can be detected based on their specific interaction with a corresponding antibody. However, this measurement system relies on specialized resources, limiting its usefulness in non-equipped centers or as a self-test. Metachromasia is a characteristic color change exhibited by certain aniline dyes upon binding to chromotropic substances. This phenomenon has been widely used in histology. Methylene blue (O-Toluidine) is an excellent metachromatic dye that changes from blue to pink upon binding to high-molecular-weight polysaccharides, such as sulfated glycan. The pink dye will then quickly turn back to blue following addition of a proportional amount of a protein with high affinity to sulfated glycan (inverted metachromacia).
Here the investigators used this approach to develop a new strip test-referred to herein as the index text-to assess the presence of dextran-sulfate-binding proteins in sputum. The investigators then assessed the accuracy of this strip test for detecting bacterial infection in sputum, by analyzing leftover sputum samples that were sent for examination to the Department of Microbiology, University hospital in Linköping.
- Conditions
- Pneumonia, Community-acquired Pneumonia, Exacerbation Copd
- Being tested
- left-over sputum
- Keywords
- point of care, HGF, innate immunity
- Medical subject headings
- Pneumonia, Community-Acquired Pneumonia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
left-over sputumDiagnostic test
Totally 467 samples were gathered from different clinics, and the diagnostic procedures and the therapeutic approaches were completely unknown to the study group. The coded samples were stored at 4-8°C and analyzed within 72 hours of sampling using the sputum strip test. From April to June 2016, a physician and the study nurse reviewed the journals. The age, sex, length of stay on ward, the clinical symptoms, the blood and sputum cultures and PCR along with the results, the X-rays, the antibiotic therapy, CRB-65 and the ultimate diagnosis code (ICD-10) were documented in Excel-files.
| Study group | Role | What they receive |
|---|---|---|
| Fresh left-over sputum | All fresh sputum samples that were sent to the Department of Microbiology between November 1 2015 and January 30 2016 under the standard requirements for sputum cultures at the accredited (ISO 17025 and 15189 beginning in 1993) laboratory were kept cold (4-8 ͦC) after analysis by microscope and cultures until it was collected and coded by the study nurse in the evening (left-over samples). Receives: Diagnostic Test: left-over sputum |
What is being measured
The primary outcome is the main question the study is designed to answer.
Negative predictive value to rule-out pneumonia
The sputum samples were collected randomly without knowledge about the patient or the ultimate diagnosis. The diagnoses were established first after the patient was dismissed from the clinic.
RESPIRATORY INFECTION Pneumonia The following criteria were used to define pneumonia diagnosis
- Clinical signs and symptoms
- Changes detected by recent chest radiography
- Received antibiotic therapy, irrespective previous antibiotic consumption.
- The ultimate diagnosis J13-J18-J690 (ICD-10). Community-acquired pneumonia: The patients without previous respiratory disease.
Hospital acquired (Nosocomial) pneumonia: Patients (n=11) acquired pneumonia at the hospital at least 48-72 hours after being admitted.
Measured: Within two years
Secondary outcomes (2)
Correlation to HGF and S100A8-A9 (Calprotectin) concentration (Elisa) in sputum
We assessed immunoreactive human HGF and calprotectin (Human S100A8/S100A9 heterodimer) concentrations by ELISA (80 randomly chosen samples) using commercially available ELISA kits (Quantikine ELISA; R\&D systems, Inc., Minneapolis, MN, USA). This method measures HGF and calprotectin in serum, plasma, culture media, and other biological fluids. Sputum samples that had been stored -20C were thawed and centrifuged at 1000 g for 10 minutes prior to analysis. The minimum detectable dose (MDD) as defined by supplier for this assay was 0.04 ng/ml for HGF and 0.086 ng/ml for calprotectin.
Measured: The samples were kept frozen after sampling -20 C and then thawed after 4 months and analyse was performed within 1 day.
Correlation to binding affinity to the parts of HGF molecule by Surface plasmon resonance
Paired analysis was performed on 47 randomly chosen samples. Measurements and ligand immobilization procedures were conducted using a Biacore 2000 system (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). Three different ligands were immobilized in separate channels on the SPR-chip. The ligands were affinity purified polyclonal antibodies directed against HGF peptides mapping at the N-terminus of human HGFβ (N-19), the N-terminus of human HGFα (N-17), and amino acids 32-176 of human HGFα (H-145). These ligands were diluted 1:10 in 10 mM acetate buffer (pH 4.5) and immobilized to carboxymethylated dextran CM5 chips
Measured: in 47 samples paired Elisa and SPR analysis was performed on samples kept in -20 C within 4 months after sampling..
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Aug 2017
- Study startNov 2015
- Primary completion5 Feb 2016
- Study completionApr 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PneumoniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 467 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Linkoeping
- Sponsor type
- University, hospital or other
- Collaborators
- Linkoeping University, PEAS Institut
- Responsible party
- Principal investigator, Fariba Nayeri, University Hospital, Linkoeping
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03256604
- Sponsor's protocol ID
- Dexact-resp
- Acronym
- self-test
- Status last verified
- Aug 2017
- First submitted
- 16 Aug 2017
- Last updated
- 22 Aug 2017
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Information regarding the samples that were included in statistic calculations, excluded cases with infection, pneumonia 1970-1980-1990, the actual cost of tests performed at our centre for diagnosis of pneumonia and the volunteers joining the feasibility test in Tables A-L
Study at a glance
From the registry record, last updated by the sponsor on 22 Aug 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Sputum Screening Test to Rule-out Pneumonia at an Early Stage
- ClinicalTrials.gov ID
- NCT03256604
- Acronym / sponsor ID
- self-test / Dexact-resp
- Conditions
- Pneumonia, Community-acquired Pneumonia, Exacerbation Copd
- Keywords
- point of care, HGF, innate immunity
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 467 participants (actual)
- Lead sponsor
- University Hospital, LinkoepingUniversity, hospital or other
- Collaborators
- Linkoeping University, PEAS Institut
- Study start
- Nov 2015 (actual)
- Primary completion
- 5 Feb 2016 (actual)
- Study completion
- Apr 2016 (actual)
- First posted
- 22 Aug 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In patients with clinical symptoms of respiratory infection, rapid identification of cases requiring antibiotic therapy is crucial to avoid development of multiple resistant bacteria. Identification of local acute-phase reactants can help assess the host's response to bacterial infection at the injury site. Here, the investigators developed an affordable, stable, feasible, and accurate diagnostic tool based on a locally produced protein with specific binding affinity to polysaccharides. The investigators further evaluated the ability of the novel test strip to rule out pneumonia.
Detailed description
A lower respiratory tract infection is a serious situation that can abruptly become complicated by sepsis, respiratory failure, lung tissue necrosis, and multiple organ dysfunction. Hence, empiric antibiotic treatment is commonly initiated as soon as infection is suspected and cultures and/or other diagnostic tests are procured, representing a major reason for antibiotic prescription. Widespread antibiotic overuse and misuse have led to the emergence of multiple resistant bacterial strains, posing a major health threat. There exists a critical need for practical solutions to prevent antibiotic overuse, especially in communities where antibiotics are available without prescription.
Pathophysiologic studies show that infection does not result from bacterial or viral overgrowth alone, but rather from the microorganisms' penetration beyond the host immune system. Therefore, infection assessment requires investigation of both microorganism presence and the defense mechanisms activated within the patient's body. Bacteria overgrowth leads to lung tissue inflammation, recruitment of white blood cells to the infected area, and chemokine and cytokine production and release, which can cause the alveoli to become filled with fluid, leading the patient to develop a cough with phlegm or pus, fever, chills, and dyspnea.
Microbiological diagnosis of lower respiratory tract infections requires assessment of the invading microorganism by examination of sputum using microscopy, quantitative culture, and PCR. However, such microbiological investigations have limited value in pneumonia management. Polymicrobial flora make it difficult to interpret cultures from patients with chronic bronchitis. It is also difficult to evaluate cultures from nosocomial pneumonia since the pathogenic bacteria are often identical to those appearing in the throat flora. Immunosuppressed patients frequently produce sputum containing low number of white blood cells. The patient's clinical signs, such as respiratory and circulatory status, are the most reliable markers for determining treatment efficacy.
In practice, most physicians choose to examine additional markers at early stages to closely monitor the effects of therapy, particularly in high-risk patients who have been admitted to intensive care units. Commonly used systemic markers include body temperature, C-reactive protein (CRP), procalcitonin (PCT), and interleukin 6 (IL-6). Hepatocyte growth factor (HGF) concentration reportedly increases during organ damage, such as that caused by infectious diseases. Studies show increased HGF concentrations in serum and exhaled-breath condensate from patients with pneumonia, with HGF presence being significantly correlated with survival. Moreover, HGF levels markedly decrease within 48 hours of initiating appropriate antibiotic therapy. Surface plasmon resonance (SPR) results indicate that HGF produced during acute infection shows high affinity for the extracellular matrix component heparan sulfate proteoglycan (HSPG). These findings suggest that HGF assessment in sputum could be a tool for detecting bacterial infection at the site of injury.
Proteins can be detected based on their specific interaction with a corresponding antibody. However, this measurement system relies on specialized resources, limiting its usefulness in non-equipped centers or as a self-test. Metachromasia is a characteristic color change exhibited by certain aniline dyes upon binding to chromotropic substances. This phenomenon has been widely used in histology. Methylene blue (O-Toluidine) is an excellent metachromatic dye that changes from blue to pink upon binding to high-molecular-weight polysaccharides, such as sulfated glycan. The pink dye will then quickly turn back to blue following addition of a proportional amount of a protein with high affinity to sulfated glycan (inverted metachromacia).
Here the investigators used this approach to develop a new strip test-referred to herein as the index text-to assess the presence of dextran-sulfate-binding proteins in sputum. The investigators then assessed the accuracy of this strip test for detecting bacterial infection in sputum, by analyzing leftover sputum samples that were sent for examination to the Department of Microbiology, University hospital in Linköping.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Fresh left-over sputum | – | Diagnostic Test: left-over sputumAll fresh sputum samples that were sent to the Department of Microbiology between November 1 2015 and January 30 2016 under the standard requirements for sputum cultures at the accredited (ISO 17025 and 15189 beginning in 1993) laboratory were kept cold (4-8 ͦC) after analysis by microscope and cultures until it was collected and coded by the study nurse in the evening (left-over samples). |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- All cases that searched the open Health care specialist facility at Linkoeping University hospital or were admitted to the ward at different clinics at the University Hospital in Linkoeping between 1st November 2015 to 30th January 2016 due to suspected respiratory infection and sputum samples were collected to be cultured at the Department of Microbiology University Hospital in Linkoeping.
Key inclusion criteria (1 listed)
- Sputum samples collected for routine diagnostic and reached the laboratory within 12 hours after Collection and considered as representative by microscopy and kept 4-8 C after Culture.
Key exclusion criteria (1 listed)
- Samples not collected as above
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| left-over sputumTotally 467 samples were gathered from different clinics, and the diagnostic procedures and the therapeutic approaches were completely unknown to the study group. The coded samples were stored at 4-8°C and analyzed within 72 hours of sampling using the sputum strip test. From April to June 2016, a physician and the study nurse reviewed the journals. The age, sex, length of stay on ward, the clinical symptoms, the blood and sputum cultures and PCR along with the results, the X-rays, the antibiotic therapy, CRB-65 and the ultimate diagnosis code (ICD-10) were documented in Excel-files. | Diagnostic test | Fresh left-over sputum |
Primary outcome
Negative predictive value to rule-out pneumonia
Time frame: Within two years
The sputum samples were collected randomly without knowledge about the patient or the ultimate diagnosis. The diagnoses were established first after the patient was dismissed from the clinic. RESPIRATORY INFECTION Pneumonia The following criteria were used to define pneumonia diagnosis 1. Clinical signs and symptoms 2. Changes detected by recent chest radiography 3. Received antibiotic therapy, irrespective previous antibiotic consumption. 4. The ultimate diagnosis J13-J18-J690 (ICD-10). Community-acquired pneumonia: The patients without previous respiratory disease. Hospital acquired (Nosocomial) pneumonia: Patients (n=11) acquired pneumonia at the hospital at least 48-72 hours after being admitted.
2 secondary outcomes
Correlation to HGF and S100A8-A9 (Calprotectin) concentration (Elisa) in sputum
Time frame: The samples were kept frozen after sampling -20 C and then thawed after 4 months and analyse was performed within 1 day.
Correlation to binding affinity to the parts of HGF molecule by Surface plasmon resonance
Time frame: in 47 samples paired Elisa and SPR analysis was performed on samples kept in -20 C within 4 months after sampling..
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Aug 2017.
- Individual participant dataSharing planned: Yes. Information regarding the samples that were included in statistic calculations, excluded cases with infection, pneumonia 1970-1980-1990, the actual cost of tests performed at our centre for diagnosis of pneumonia and the volunteers joining the feasibility test in Tables A-L
Related trials for Pneumonia
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Not yet recruitingPhase 3
Dapagliflozin for Long COVID Syndrome
COVID - 19, Long COVID Syndrome
RecruitingPhase 3
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Chronic Graft-versus-host-disease
RecruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pneumonia and Community-acquired Pneumonia, run by University Hospital, Linkoeping at 1 site in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Aug 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Negative predictive value to rule-out pneumonia (time frame: Within two years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Aug 2017.